Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1818

Shown on this page

Current sort

Live official records

Conditions: Multiple Myeloma
Interventions: Cilta-cel; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2041
U.S. locations: 28
States / cities: Phoenix, Arizona • Duarte, California • San Francisco, California + 21 more

Conditions: Glanzmann Thrombasthenia
Interventions: HMB-001; Drug
Lead sponsor: Hemab ApS; Industry
Eligibility: 18 Years to 67 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: La Jolla, California • New Orleans, Louisiana • Rochester, Minnesota + 2 more

Conditions: Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
Interventions: UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM); Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Crohn Disease
Interventions: Icotrokinra, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,092 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 61
States / cities: Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 49 more

Conditions: Solid Tumors
Interventions: IBI3020; Drug
Lead sponsor: Fortvita Biologics (USA)Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more

Conditions: Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3, Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma AJCC v7, Stage II Soft Tissue Sarcoma AJCC v7, Undifferentiated Pleomorphic Sarcoma
Interventions: Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Talimogene Laherparepvec; Procedure · Radiation · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 16
States / cities: Phoenix, Arizona • Duarte, California • Orange, California + 12 more

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Midazolam, Oral Placebo, Intranasal Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more

Conditions: Neoplasms
Interventions: JNJ-1761981, Cetrelimab; Drug
Lead sponsor: Johnson & Johnson Enterprise Innovation Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Jacksonville, Florida • Rochester, Minnesota • The Bronx, New York + 1 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Lazertinib, Chemotherapy: Pemetrexed, Chemotherapy: Carboplatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 150
States / cities: Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more

Conditions: Multiple Myeloma
Interventions: JNJ-79635322, Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 38 more

Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
Interventions: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more

Conditions: Central Line Associated Blood Stream Infections (CLABSI)
Interventions: (taurolidine and heparin) catheter lock solution, Heparin; Drug
Lead sponsor: CorMedix Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Doral, Florida + 14 more

About this Mayo Clinic institution page

What this page lists: ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mayo Clinic

Filter and sort this campus

Live official records

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

A Study of JNJ-1761981 in Participants With Solid Tumors

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

About this Mayo Clinic institution page